1. Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, Duan S, Eiwegger T, Eljaszewicz A, Ferstl R and others. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol 2016;138(4):984-1010.
2. Catalan-Dibene J, McIntyre LL, Zlotnik A. Interleukin 30 to Interleukin 40. J Interferon Cytokine Res 2018;38(10):423-49.
3. Gallagher G, Dickensheets H, Eskdale J, Izotova LS, Mirochnitchenko OV, Peat JD, Vazquez N, Pestka S, Donnelly RP, Kotenko SV. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun 2000;1(7):442-50.
4. Azuma YT, Nakajima H, Takeuchi T. IL-19 as a potential therapeutic in autoimmune and inflammatory diseases. Curr Pharm Des 2011;17(34):3776-80.
5. Chang C, Magracheva E, Kozlov S, Fong S, Tobin G, Kotenko S, Wlodawer A, Zdanov A. Crystal structure of interleukin-19 defines a new subfamily of helical cytokines. J Biol Chem 2003;278(5):3308-13.
6. Li HH, Lin YC, Chen PJ, Hsiao CH, Lee JY, Chen WC, Tzung TY, Wu JC, Chan g MS. Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br J Dermatol 2005;153(3):591-5.
7. Chen PJ, Wei CC, Wang C, Chen FW, Hsu YH, Chang MS. Promoter analysis of interleukin 19. Biochem Biophys Res Commun 2006;344(3):713-20.
8. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011;29:71-109.
9. Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K, Thilo J, Asadullah K, Sterry W, Volk HD and others. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008;83(5):1181-93.
10. Fickenscher H, Hör S, Küpers H, Knappe A, Wittmann S, Sticht H. The interleukin-10 family of cytokines. Trends Immunol 2002;23(2):89-96.
11. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002;168(11):5397-402.
12. Li Y, Messina C, Bendaoud M, Fine DH, Schreiner H, Tsiagbe VK. Adaptive immune response in osteoclastic bone resorption induced by orally administered Aggregatibacter actinomycetemcomitans in a rat model of periodontal disease. Mol Oral Microbiol 2010;25(4):275-92.
13. Horiuchi H, Parajuli B, Wang Y, Azuma YT, Mizuno T, Takeuchi H, Suzumura A. Interleukin - 19 acts as a negative autocrine regulator of activated microglia. PLoS One 2015;10(3):e0118640.
14. Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, Sterry W, Asadullah K, Sabat R. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006;15(12):991-1004.
15. Yano S, Banno T, Walsh R, Blumenberg M. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin-1. J Cell Physiol 2008;214(1):1-13.
16. Bettaccini AA, Baj A, Accolla RS, Basolo F, Toniolo AQ. Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogene tically relevant genes. BMC Microbiol 2005;5:20.
17. Zhong H, Wu Y, Belardinelli L, Zeng D. A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-alpha increase. Am J Respir Cell Mol Biol 2006;35(5):587-92.
18. Huang F, Kao CY, Wachi S, Thai P, Ryu J, Wu R. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J Immunol 2007;179(10):6504 -13.
19. Huang F, Wachi S, Thai P, Loukoianov A, Tan KH, Forteza RM, Wu R. Potentiation of IL-19 expression in airway epithelia by IL-17A and IL-4/IL-13: important implications in asthma. J Allergy Clin Immunol 2008;121(6):1415-21, 1421.e1-3.
20. Tian Y, Sommerville LJ, Cuneo A, Kelemen SE, Autieri MV. Expression and suppressive effects of interleukin-19 on vascular smooth muscle cell pathophysiology and development of intimal hyperplasia. Am J Pathol 2008;173(3):901-9.
21. 小野尚重，東 泰孝．IL-19の抗炎症作用を活かした治療への応用．日本薬理学雑誌 2021;156(5):288-91.
22. 東 泰孝、竹内正吉. インターロイキン-19 による腸免疫制御システムの調節－炎症性 腸疾患モデルマウスからの知見. 日本薬理学雑誌 20014;143(6), 275-8.
23. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 2001;167(7):3545-9.
24. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, Eagan M, Foster D, Haldeman BA, Hammond A and others. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001;104(1):9-19.
25. Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, Brandt C, Jelinek L, Madden K, McKernan PA and others. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002;277(49):47517-23.
26. Gallagher G, Eskdale J, Jordan W, Peat J, Campbell J, Boniotto M, Lennon GP, Dickensheets H, Donnelly RP. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol 2004;4(5):615-26.
27. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75(2):263-74.
28. Azuma YT, Matsuo Y, Nakajima H, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Takeuchi T. Interleukin-19 is a negative regulator of innate immunity and critical for colonic protection. J Pharmacol Sci 2011;115(2):105-11.
29. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000;164(12):6166-73.
30. Taniguchi Y, Yoshioka N, Nakata K, Nishizawa T, Inagawa H, Kohchi C, Soma G. Mechanism for maintaining homeostasis in the immune system of the intestine. Anticancer Res 2009;29(11):4855-60.
31. Tlaskalova-Hogenova H, Tuckova L, Mestecky J, Kolinska J, Rossmann P, Stepankova R, Kozakova H, Hudcovic T, Hrncir T, Frolova L and others. Interaction of mucosal microbiota with the innate immune system. Scand J Immunol 2005;62 Suppl 1:106-13.
32. Seksik P, Sokol H, Lepage P, Vasquez N, Manichanh C, Mangin I, Pochart P, Doré J, Marteau P. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther 2006;24 Suppl 3:11-8.
33. Chichlowski M, Hale LP. Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad. Am J Physiol Gastrointest Liver Physiol 2008;295(6):G1139-49.
34. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008;14(27):4280-8.
35. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3(7):521-33.
36. Thompson-Chagoyán OC, Maldonado J, Gil A. Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr 2005;24(3):339-52.
37. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75(2):253-61.
38. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993;75(2):274-82.
39. Zijlstra FJ, Garrelds IM, van Dijk AP, Wilson JH. Experimental colitis in mice: effects of olsalazine on eicosanoid production in colonic tissue. Agents Actions 1992;Spec No:C76-8.
40. Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182(5):1281-90.
41. Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998;188(10):1929 -39.
42. Valenzuela DM, Murphy AJ, Frendewey D, Gale NW, Economides AN, Auerbach W, Poueymirou WT, Adams NC, Rojas J, Yasenchak J and others. High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat Biotechnol 2003;21(6):652-9.
43. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69(2):238-49.
44. Suresh A, Sodhi A. Production of interleukin-1 and tumor necrosis factor by bone marrowderived macrophages: effect of cisplatin and lipopolysaccharide. Immunol Lett 1991;30(1):93 - 100.
45. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118(2):229-41.
46. Van Heel DA, McGovern DP, Jewell DP. Crohn's disease: genetic susceptibility, bacteria, and innate immunity. Lancet 2001;357(9272):1902-4.
47. Naito Y, Takagi T, Handa O, Ishikawa T, Nakagawa S, Yamaguchi T, Yoshida N, Minami M, Kita M, Imanishi J and others. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol 2003;18(5):560- 9.
48. Kojouharoff G, Hans W, Obermeier F, Männel DN, Andus T, Schölmerich J, Gross V, Falk W. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997;107(2):353-8.
49. Naito Y, Takagi T, Uchiyama K, Kuroda M, Kokura S, Ichikawa H, Yanagisawa R, Inoue K, Takano H, Satoh M and others. Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice. Int J Mol Med 2004;14(2):191-6.
50. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA. IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A 2001;98(23):13249-54.
51. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994;107(6):1643-52.
52. Hummelshoj L, Ryder LP, Poulsen LK. The role of the interleukin-10 subfamily members in immunoglobulin production by human B cells. Scand J Immunol 2006;64(1):40-7.
53. Ido A, Numata M, Kodama M, Tsubouchi H. Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. J Gastroenterol 2005;40(10):925-31.
54. Tezuka H, Abe Y, Asano J, Sato T, Liu J, Iwata M, Ohteki T. Prominent role for plasmacytoid dendritic cells in mucosal T cell-independent IgA induction. Immunity 2011;34(2):247-57.
55. Morokata T, Ishikawa J, Ida K, Yamada T. C57BL/6 mice are more susceptible to antigen - induced pulmonary eosinophilia than BALB/c mice, irrespective of systemic T helper 1/T helper 2 responses. Immunology 1999;98(3):345-51.
56. Menon JN, Bretscher PA. Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge. Eur J Immunol 1996;26(1):243-9.
57. Fujimoto Y, Azuma YT, Matsuo Y, Kuwamura M, Kuramoto N, Miki M, Azuma N, Teramoto M, Nishiyama K, Izawa T and others. Interleukin-19 contributes as a protective factor in experimental Th2-mediated colitis. Naunyn Schmiedebergs Arch Pharmacol 2017;390(3):261- 8.
58. Fujimoto Y, Fujita T, Kuramoto N, Kuwamura M, Izawa T, Nishiyama K, Yoshida N, Nakajima H, Takeuchi T, Azuma YT. The role of interleukin-19 in contact hypersensitivity. Biol Pharm Bull 2018;41(2):182-9.
59. Curtin NM, Mills KH, Connor TJ. Psychological stress increases expression of IL-10 and its homolog IL-19 via beta-adrenoceptor activation: reversal by the anxiolytic chlordiazepoxide. Brain Behav Immun 2009;23(3):371-9.
60. Hsing CH, Chiu CJ, Chang LY, Hsu CC, Chang MS. IL-19 is involved in the pathogenesis of endotoxic shock. Shock 2008;29(1):7-15.
61. Liu X, Zhou H, Huang X, Cui J, Long T, Xu Y, Liu H, Yu R, Zhao R, Luo G and others. A broad blockade of signaling from the IL-20 family of cytokines potently attenuates collagen-induced arthritis. J Immunol 2016;197(8):3029-37.
62. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers 2016;2:16045.
63. Denning NL, Aziz M, Gurien SD, Wang P. DAMPs and NETs in sepsis. Front Immunol 2019;10:2536.
64. Akira S, Takeda K. Functions of toll-like receptors: lessons from KO mice. C R Biol 2004;327(6):581-9.
65. Zhao X, Yin L, Fang L, Xu L, Sun P, Xu M, Liu K, Peng J. Protective effects of dioscin against systemic inflammatory response syndromevia adjusting TLR2/MyD88/NF κb signal pathway. Int Immunopharmacol 2018;65:458-69.
66. Hegde A, Zhang H, Moochhala SM, Bhatia M. Neurokinin-1 receptor antagonist treatment protects mice against lung injury in polymicrobial sepsis. J Leukoc Biol 2007;82(3):678-85.
67. Renckens R, Roelofs JJ, ter Horst SA, van 't Veer C, Havik SR, Florquin S, Wagenaar GT, Meijers JC, van der Poll T. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005;175(10):6764-71.
68. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 2008;60(7):805-12.
69. Metelitsa LS, Wu HW, Wang H, Yang Y, Warsi Z, Asgharzadeh S, Groshen S, Wilson SB, Seeger RC. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 2004;199(9):1213-21.
70. Ottaviani C, Nasorri F, Bedini C, de Pità O, Girolomoni G, Cavani A. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 2006;36(1):118-28.
71. Fehér K. Single stranded DNA immune modulators with unmethylated CpG motifs: structure and molecular recognition by Toll-like receptor 9. Curr Protein Pept Sci 2019;20(11):1060-8.
72. Ferret-Bernard S, Lacroix-Lamandé S, Remot A, Metton C, Bernardet N, Charley B, Drouet F, Laurent F. Mesenteric lymph node cells from neonates present a prominent IL-12 response to CpG oligodeoxynucleotide via an IL-15 feedback loop of amplification. Vet Res 2011;42:19.
73. Ferreira-Duarte AP, Pinheiro-Torres AS, Takeshita WM, Gushiken VO, Roncalho-Buck IA, Anhê GF, DeSouza IA. Airway exposure to Staphylococcal enterotoxin type B (SEB) enhances the number and activity of bone marrow neutrophils via the release of multiple cytokines. Int Immunopharmacol 2020;78:106009.
74. Wegermann K, Suzuki A, Mavis AM, Abdelmalek MF, Diehl AM, Moylan CA. Tackling nonalcoholic fatty liver disease: three targeted populations. Hepatology 2021;73(3):1199-206.
75. Balakrishnan M, Loomba R. The role of noninvasive tests for differentiating NASH from NAFL and diagnosing advanced fibrosis among patients with NAFLD. J Clin Gastroenterol 2020;54(2):107-13.
76. Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21(11):3863.
77. Schwabe RF, Tabas I, Pajvani UB. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology 2020;158(7):1913-28.
78. Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, Kirsch RE, Hall PeL. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 2003;18(11):1272-82.
79. Shiri-Sverdlov R, Wouters K, van Gorp PJ, Gijbels MJ, Noel B, Buffat L, Staels B, Maeda N, van Bilsen M, Hofker MH. Early diet-induced non-alcoholic steatohepatitis in APOE2 knockin mice and its prevention by fibrates. J Hepatol 2006;44(4):732-41.
80. Kita Y, Takamura T, Misu H, Ota T, Kurita S, Takeshita Y, Uno M, Matsuzawa -Nagata N, Kato K, Ando H and others. Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS One 2012;7(9):e43056.
81. Matsumoto M, Hada N, Sakamaki Y, Uno A, Shiga T, Tanaka C, Ito T, Katsume A, Sudoh M. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol 2013;94(2):93-103.
82. Ioannou GN. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol Metab 2016;27(2):84-95.
83. Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol 2018;15(6):349-64.
84. Wu Q, Wang Q, Fu J, Ren R. Polysaccharides derived from natural sources regulate triglyceride and cholesterol metabolism: a review of the mechanisms. Food Funct 2019;10(5):2330 -9.
85. Igal RA, Sinner DI. Stearoyl-CoA desaturase 5 (SCD5), a Δ-9 fatty acyl desaturase in search of a function. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866(1):158840.
86. Ouyang S, Mo Z, Sun S, Yin K, Lv Y. Emerging role of Insig-1 in lipid metabolism and lipid disorders. Clin Chim Acta 2020;508:206-2.
87. Wang M, Ma LJ, Yang Y, Xiao Z, Wan JB. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review. Crit Rev Food Sci Nutr 2019;59(sup1):S116 -29.
88. Tahri-Joutey M, Andreoletti P, Surapureddi S, Nasser B, Cherkaoui-Malki M, Latruffe N. Mechanisms mediating the regulation of peroxisomal fatty acid beta-oxidation by PPARα. Int J Mol Sci 2021;22(16):8969.
89. Zhou X, Xu J, Shi Y, Ye JM. Discovery of novel anti-diabetic drugs by targeting lipid metabolism. Curr Drug Targets 2015;16(12):1372-80.
90. Yata Y, Gotwals P, Koteliansky V, Rockey DC. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 2002;35(5):1022-30.
91. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 2017;14(7):397-411.
92. Zhong X, Huang M, Kim HG, Zhang Y, Chowdhury K, Cai W, Saxena R, Schwabe RF, Liangpunsakul S, Dong XC. SIRT6 protects against liver fibrosis by deacetylation and suppression of SMAD3 in hepatic stellate cells. Cell Mol Gastroenterol Hepatol 2020;10(2):341-64.
93. Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells 2020;9(4):875.
94. El-Kehdy H, Najar M, De Kock J, Agha DM, Rogiers V, Merimi M, Lagneaux L, Sokal EM, Najimi M. Inflammation differentially modulates the biological features of adult derived human liver stem/progenitor cells. Cells 2020;9(7):1640.
95. Horn CL, Morales AL, Savard C, Farrell GC, Ioannou GN. Role of cholesterol-associated steatohepatitis in the development of NASH. Hepatol Commun 2022;6(1):12-35.
論文の公開元へ
